Also see: Dendreon, Tiffany: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
estimates, target raised at UBS. Shares of AGU now seen reaching $115. Estimates also raised on improving gross margins in all three strategic business units. Buy rating.
estimates, target increased at Citigroup. Shares of ARCO now seen reaching $32. Estimates also raised on NOLAD turnaround and margin boosts. Buy rating.
estimates, target lowered at UBS. Shares of ATML now seen reaching $18. Estimates also lowered as weaker macro slows growth. Buy rating.
(ATVI - Get Report)
estimates higher at UBS. TVI estimates were raised through 2012. New digital business models enhance margin, drive growth. Maintain $14 price target and Buy rating.
estimates, target lowered at UBS. Shares of BRKR now seen reaching $21. Estimates also lowered on higher SG&A costs. Buy rating.
estimates lowered at UBS through 2011. Gross margins decline amid higher commodity costs. Maintain $10 price target and Buy rating.
(CSCO - Get Report)
target lowered at Citigroup to $17.50. Restructuring and macro headwinds weight on NT outlook. Hold rating.
numbers boosted at Credit Suisse. Shares of DUK now seen reaching $19. Estimates also upped, to match the company's new guidance. Neutral rating.
DaVita estimates raised at UBS through 2012. Solid guidance and lower EPO/better Medicare rate. Maintain $100 price target and Buy rating.
(EMR - Get Report)
estimates, target cut at Credit Suisse. EMR estimates were reduced through 2013. Company is leveraged to lower macroeconomic growth. Outperform rating and new $59 price target.
(G - Get Report)
estimates, target increased at Citigroup. Shares of G now seen reaching $18. Estimates also raised on strong 2Q. Hold rating.
(HPQ - Get Report)
numbers reduced at Barclays. Shares of HPQ now seen reaching $37. Estimates also cut, given lower PC demand. Equal-weight rating.
(ICE - Get Report)
numbers cut at Barclays. Shares of ICE now seen reaching $148. Estimates also lowered, given the company's new volume forecast. Overweight rating.
ICE estimates, target lowered at UBS. Shares of ICE now seen reaching $140, according to UBS. Estimates also lowered on updated volume assumptions. Buy rating.